Xilio Therapeutics, Inc. - XLO STOCK NEWS

Xilio Therapeutics (Nasdaq: XLO) has appointed Caroline Hensley as chief legal officer. Hensley joins from Seres Therapeutics, where she served as senior vice president, assistant general counsel and chief compliance officer, overseeing corporate legal and compliance matters. Her experience includes managing capital markets transactions, clinical development activities, commercial launches, and FDA regulatory compliance. Previously, she worked as a corporate associate at Latham & Watkins, representing biotechnology companies in various transactions. Hensley holds a B.A. in economics from the University of Texas at Austin and a J.D. from Boston University School of Law.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to a new employee. The grant, effective December 1, 2024, consists of non-qualified stock options to purchase 8,400 shares of common stock at an exercise price of $1.09 per share, matching the closing price on November 29, 2024.

The options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting monthly over three years. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics announced initial clinical data from Phase 1C trial evaluating vilastobart combined with atezolizumab in advanced solid tumor patients. The combination showed promising anti-tumor activity, including two unconfirmed partial responses in patients with immunologically 'cold' tumors. A notable complete resolution of a metastatic liver lesion was observed in a patient with microsatellite stable colorectal cancer (MSS CRC). The treatment was generally well-tolerated, with no Grade 4 or 5 treatment-related adverse events reported. Initial Phase 2 data for the combination in metastatic MSS CRC patients is expected in Q4 2024.

Xilio Therapeutics (Nasdaq: XLO) reported Q3 2024 financial results and pipeline updates. The company will present initial Phase 1C data for vilastobart combined with atezolizumab at SITC Annual Meeting. Key financial metrics include cash position of $61.3 million, license revenue of $2.3 million, and net loss of $14.0 million. R&D expenses decreased to $10.8 million from $11.1 million year-over-year, while G&A expenses remained stable at $6.3 million. The company expects current cash to fund operations through Q2 2025.

Xilio Therapeutics (Nasdaq: XLO) announced it will present initial Phase 1C dose escalation data for XTX101 (vilastobart) in combination with atezolizumab at the SITC 39th Annual Meeting. The presentation will focus on results from patients with advanced solid tumors. The late-breaker poster session will take place on November 8, 2024, at the George R. Brown Convention Center in Houston, Texas. XTX101 is a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody being developed for cancer treatment.

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced an upcoming poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place in Houston, Texas, from November 6-10, 2024.

The company plans to present preclinical data from its tumor-activated SELECTIVE EFFECTOR-ENHANCED CELL ENGAGER (SEECR) format. The poster, titled "Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models," will be presented on Saturday, Nov. 9, 2024. The presentation will be available for viewing during the lunch and poster viewing session from 12:15 – 1:45 p.m. CST and during the poster reception from 7:10 – 8:40 p.m. CST at the George R. Brown Convention Center.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has announced the granting of stock options to three new employees. The Compensation Committee approved non-qualified stock options to purchase 101,000 shares of common stock under the company's 2022 Inducement Stock Incentive Plan. These options, effective October 1, 2024, have an exercise price of $0.75 per share, matching the closing price on that date. The options have a ten-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) for inducement material to new employment.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's president and CEO, René Russo, Pharm.D., will engage in a fireside chat on September 4, 2024, at 7:00 am EDT.

Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Xilio's website. The webcast will remain available for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the company's latest developments and strategies in the field of cancer treatment.

Xilio Therapeutics (Nasdaq: XLO) reported Q2 2024 financial results and pipeline updates. Key highlights include:

1. Initiated Phase 2 trial of XTX101 with atezolizumab in MSS CRC patients.

2. Started Phase 1B monotherapy dose expansion for XTX301 in advanced solid tumors.

3. Expects to report clinical data for XTX101 and XTX301 in Q4 2024.

4. Q2 2024 ended with $74.9 million in cash, anticipating runway into Q2 2025.

5. Q2 2024 financial results: $2.4 million license revenue, $11.2 million R&D expenses, $5.8 million G&A expenses, $13.9 million net loss.

6. Promoted Chris Frankenfield to CFO while retaining COO role.

7. Advancing research-stage tumor-activated bispecifics and immune cell engagers.